To investigate the clinical value of targeted therapy combined with immune neoadjuvant regimen in the treatment of elderly patients with advanced hepatocellular carcinoma (HCC) and to analyze the value of monitoring eosinophil (EOS) and vascular endothelial growth factor (VEGF) levels during treatment.
A retrospective analysis was conducted on 160 elderly patients with advanced HCC admitted to Yichang Central People's Hospital from January 2020 to January 2023. According to the treatment regimens, the patients were divided into group A (targeted therapy alone, n=51), group B (immunotherapy alone, n=43), and group C (targeted therapy combined with immunotherapy, n=66). The modified response evaluation criteria in solid tumors (mRECIST) was used to evaluate the therapeutic efficacy. The treatment-related adverse events were recorded. The patients were followed until December 2024. The overall survival (OS) and progression-free survival (PFS) were recorded. The levels of peripheral blood EOS and serum VEGF were measured before treatment and after 3 medication cycles. Receiver operating characteristic (ROC) curves were plotted to analyze the value of differences of peripheral blood EOS and serum VEGF levels before and after treatment in predicting the disease control rate (DCR). SPSS 26.0 was used for statistical analysis. Data comparison between two groups was performed using One-way ANOVA, χ2 test or Fisher's exact probability test depending on data type.
The objective response rate (ORR) and DCR in group C were significantly higher than those in groups A and B (P<0.05), but there were no statistical differences in ORR and DCR between group A and group B (P>0.05). There were no statistically significant differences in the incidence of ≥ Ⅲ adverse events among the three groups (P>0.05). The OS was 10.46 months (95%CI 0.340–9.794) in group A, 10.88 months (95%CI 0.389–10.115) in group B, and 14.18 months (95%CI 0.323–13.543) in group C, without statistical significance between groups A and B (Log-rank χ2=10.446, P=0.504) and with longer OS in group C than those in groups A and B (Log-rank χ2=31.030, P<0.001). PFS was 5.06 months (95%CI 0.367–4.432) in group A, 5.19 months (95%CI 0.361–4.486) in group B, and 6.36 months (95%CI 0.294–5.784) in group C, without statistically differences among the three groups (Log-rank χ2=3.987, P=0.136). No statistical differences were found in peripheral blood EOS and serum VEGF levels among the three groups before treatment (P>0.05). After 3 medication cycles, the peripheral blood EOS levels in all groups were enhanced as compared with those before treatment (P<0.05), while serum VEGF levels decreased as compared with those before treatment (P<0.05). Moreover, after treatment, group C had higher EOS level and lower VEGF level than groups A and B; Group C had greater difference in EOS and VEGF levels before and after treatment than groups A and B; the differences were statistically significant (P<0.05). EOS difference (best cut-off value = 1.24, AUC = 0.845, 95%CI 0.778–0.911, sensitivity 0.780, specificity 0.845, P<0.001) and VEGF difference (best cut-off value = 49.26, AUC = 0.786, 95%CI 0.713–0.859, sensitivity 0.700, specificity 0.755, P<0.001) before and after treatment had certain value in predicting whether patients would achieve DCR after treatment. The combination of the two had the highest predictive value (AUC = 0.894, 95%CI 0.842–0.947, sensitivity 0.920, specificity 0.818, P<0.001).
Targeted therapy combined with immunotherapy can effectively enhance therapeutic efficacy and prolong the survival time in elderly patients with advanced HCC without increasing adverse events. The differences in peripheral blood EOS and serum VEGF levels before treatment and after 3 medication cycles have certain value in predicting whether patients will achieve DCR, and can be used as predictors of treatment response in elderly patients with advanced HCC.
京公网安备11010802044758号